| 免疫抑制剂联合生物制剂对炎症性肠病患者营养状况及炎症因子的影响 |
| |
| 引用本文： | 黄慧峰,张艳,陈文晓,彭玄杰,叶克平.免疫抑制剂联合生物制剂对炎症性肠病患者营养状况及炎症因子的影响[J].中华全科医学,2019,17(5):862-864. |
| |
| 作者姓名： | 黄慧峰 张艳 陈文晓 彭玄杰 叶克平 |
| |
| 作者单位： | 1. 台州市第一人民医院消化内科, 浙江 台州 318000; |
| |
| 基金项目： | 浙江省医药卫生科技计划项目(2018KY895) |
| |
| 摘 要： | 目的 分析免疫抑制剂联合生物制剂对炎症性肠病患者营养状况及炎症因子的影响。 方法 选择台州市第一人民医院2018年1—12月治疗的72例炎症性肠病患者，根据不同疗法将其纳入对照组与观察组各36例，对照组给予免疫抑制剂硫唑嘌呤治疗，观察组给予免疫抑制剂硫唑嘌呤联合生物制剂英夫利西单抗治疗，对比2组的临床疗效、营养状况、炎症因子以及不良反应情况。 结果 观察组总有效率(94.4%)高于对照组(77.8%)，治疗后的血清白蛋白、转铁蛋白、前白蛋白、血红蛋白(42.1±5.0)g/L、(2.8±0.5)g/L、(251.7±51.3)mg/L、(133.5±19.5)g/L]优于对照组(36.9±5.2)g/L、(2.5±0.3)g/L、(232.4±44.8)mg/L、(120.4±10.7)g/L]，治疗后的TNF-α、IL-4、IL-10、IL-17(117.3±19.0)pg/L、(11.0±1.8)pg/L、(7.4±1.1)pg/L、(187.3±38.2)pg/L]优于对照组(186.6±38.3)pg/L、(16.5±2.4)pg/L、(10.9±1.7)pg/L、(285.4±32.7)pg/L]，差异均有统计学意义(均P<0.05)。观察组不良反应发生率(16.7%)与对照组(13.9%)相当，差异无统计学意义(P>0.05)。 结论 免疫抑制剂联合生物制剂对炎症性肠病患者的疗效显著，可明显改善患者的营养状况，降低炎症因子水平，且安全性高。
|
| 关 键 词： | 免疫抑制剂 生物制剂 炎症性肠病 营养状况 炎症因子 |
| 收稿时间： | 2019-01-20 |
Effects of immunosuppressive agents combined with biological agents on nutritional status and inflammatory factors in patients with inflammatory bowel disease |
| |
| Affiliation: | Department of Gastroenterology, the First People's Hospital of Taizhou City, Taizhou, Zhejiang 318000, China |
| |
| Abstract: | Objective To analyze the effects of immunosuppressive agents combined with biological agents on nutritional status and inflammatory factors in patients with inflammatory bowel disease. Methods Seventy-two patients with inflammatory bowel disease in our hospital from January to December 2018 were selected. According to different therapies, 36 patients in the control group and 36 patients in the observation group were included. The control group was treated with azathioprine, an immunosuppressant, and the observation group was treated with azathioprine combined with infliximab, a biological agent. The clinical efficacy, nutritional status, inflammatory factors and adverse reactions of the two groups were compared. Results The total effective rate of the observation group (94.4%) was higher than that of the control group (77.8%). After treatment, the serum albumin, transferrin, prealbumin and hemoglobin in the observation group (42.1±5.0)g/L, (2.8±0.5)g/L, (251.7±51.3)mg/L, (133.5±19.5)g/L] were better than those in the control group (36.9±5.2)g/L, (2.5±0.3)g/L, (232.4±44.8)mg/L, (120.4±10.7)g/L], TNF-alpha, IL-4, IL-10, IL-17 in the observation group (117.3±19.0)pg/L, (11.0±1.8)pg/L, (7.4±1.1)pg/L, (187.3±38.2)pg/L] was superior to the control group (186.6±38.3)pg/L, (16.5±2.4)pg/L, (10.9±1.7)pg/L, (285.4±32.7)pg/L]. There were significant differences among the groups (all P<0.05). The incidence of adverse reactions in the observation group (16.7%) was similar to that in the control group (13.9%). There was no significant difference between the two groups (P>0.05). Conclusion Immunosuppressive agents combined with biological agents are effective in the treatment of inflammatory bowel disease, which can significantly improve the nutritional status of patients and reduce the level of inflammatory factors, and high safety. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载全文 |
|
